Literature DB >> 33535633

What Are the Expectations for Cardiac Resynchronization Therapy? A Validation of Two Response Definitions.

Toshiko Nakai1, Yukitoshi Ikeya1, Rikitake Kogawa1, Naoto Otsuka1, Yuji Wakamatsu1, Sayaka Kurokawa1, Kimie Ohkubo1, Koichi Nagashima1, Yasuo Okumura1.   

Abstract

BACKGROUND: The definition of response to cardiac resynchronization therapy (CRT) varies across clinical trials. There are two main definitions, i.e., echocardiographic response and functional response. We assessed which definition was more reasonable.
METHODS: In this study of 260 patients who had undergone CRT, an echocardiographic response was defined as a reduction in a left ventricular end-systolic volume of greater than or equal to 15% or an improvement in left ventricular ejection fraction of greater than or equal to 5%. A functional response was defined as an improvement of at least one class category in the New York Heart Association functional classification. We assessed the response to CRT at 6 months after device implantation, based on each definition, and investigated the relationship between response and clinical outcomes.
RESULTS: The echocardiographic response rate was 74.2%. The functional response rate was 86.9%. Non-responder status, based on both definitions, was associated with higher all-cause mortality. Cardiac death was only associated with functional non-responder status (hazard ratio (HR) 2.65, 95% confidence interval (CI) 1.19-5.46, p = 0.0186) and heart failure hospitalization (HR 2.78, 95% CI, 1.29-5.26, p = 0.0111).
CONCLUSION: After CRT implantation, the functional response definition of CRT response is associated with a higher response rate and better clinical outcomes than that of the echocardiographic response definition, and therefore it is reasonable to use the functional definition to assess CRT response.

Entities:  

Keywords:  NYHA functional class; cardiac resynchronization therapy; mortality; responder

Year:  2021        PMID: 33535633     DOI: 10.3390/jcm10030514

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  4 in total

1.  Fifteen-Year Differences in Indications for Cardiac Resynchronization Therapy in International Guidelines-Insights from the Heart Failure Registries of the European Society of Cardiology.

Authors:  Agata Tymińska; Krzysztof Ozierański; Emil Brociek; Agnieszka Kapłon-Cieślicka; Paweł Balsam; Michał Marchel; Maria G Crespo-Leiro; Aldo P Maggioni; Jarosław Drożdż; Grzegorz Opolski; Marcin Grabowski
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

2.  Prognostic importance of the Controlling Nutritional Status (CONUT) score in patients undergoing cardiac resynchronisation therapy.

Authors:  Yukitoshi Ikeya; Yuki Saito; Toshiko Nakai; Rikitake Kogawa; Naoto Otsuka; Yuji Wakamatsu; Sayaka Kurokawa; Kimie Ohkubo; Koichi Nagashima; Yasuo Okumura
Journal:  Open Heart       Date:  2021-10

3.  Prognostic value of the MELD-XI score in patients undergoing cardiac resynchronization therapy.

Authors:  Yuki Saito; Toshiko Nakai; Yukitoshi Ikeya; Rikitake Kogawa; Naoto Otsuka; Yuji Wakamatsu; Sayaka Kurokawa; Kimie Ohkubo; Koichi Nagashima; Yasuo Okumura
Journal:  ESC Heart Fail       Date:  2022-01-04

4.  Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study.

Authors:  Mohammad Abumayyaleh; Jonathan Demmer; Carina Krack; Christina Pilsinger; Ibrahim El-Battrawy; Michael Behnes; Assem Aweimer; Andreas Mügge; Siegfried Lang; Ibrahim Akin
Journal:  Am J Cardiovasc Drugs       Date:  2022-03-30       Impact factor: 3.283

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.